Bristol-Myers Squibb Co Virtual Investor Event to Discuss AAD VMX Highlights Transcript

Apr 23, 2021 / 02:30PM GMT
Timothy Power - Bristol-Myers Squibb Company - VP & Head of IR

Good morning. This is Tim Power from Bristol-Myers Squibb, and you're all very welcome to our presentation at AAD 2021. As you know, we presented some really important data this morning for our TYK2 agent, deucravacitinib, and we're looking forward to discussing that with you today.

And I'm joined for today's presentation by 2 speakers, Mary Beth Harler, our Senior Vice President for Immunology and Fibrosis, Global Drug Development; and by Chris Boerner, our Chief Commercialization Officer. Samit Hirawat, our Chief Medical Officer; and Giovanni Caforio, our Board Chair and CEO, are also joining me this morning for Q&A.

And I'll refer you to this slide for our forward-looking statement. And with that, I'll hand over to Mary Beth to get the presentation started.

Mary Beth Harler - Bristol-Myers Squibb Company - Senior VP & Head of Immunology and Fibrosis Development - Bristol

Thank you, Tim. Good morning, everyone. It's great to be here with you during AAD to discuss the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot